Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This drug is a component of pneumococcal conjugate vaccines, consisting of the purified capsular polysaccharide from *Streptococcus pneumoniae* serotype 9V covalently linked to the nontoxic diphtheria toxin variant CRM197 as a carrier protein. The conjugation to CRM197 enhances immunogenicity by inducing a T-cell dependent immune response, resulting in robust and long-lasting immunity even in young children. It is used for active immunization against invasive diseases (such as pneumonia and bacteremia) caused by *S. pneumoniae* serotype 9V, and is included in multivalent vaccines like PCV13 (Prevnar 13), PCV15 (Vaxneuvance), and PCV20 (Prevnar 20)[1][3][6]. These vaccines are administered intramuscularly for prevention of pneumococcal disease across various age groups.
- Brand names
- Prevnar 13Prevnar13Prevnar-13VaxneuvancePrevnar 20Prevnar20Prevnar-20
- Other names
- pneumococcal capsular polysaccharide type 9V CRM197 conjugate antigenS. pneumoniae serotype 9V CRM197 conjugate antigen
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen.